Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12615001081505
Ethics application status
Approved
Date submitted
14/09/2015
Date registered
14/10/2015
Date last updated
8/01/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
The Effects of Probiotics on Depression: Can a Daily Drink of Good Bacteria Improve Mental Wellbeing?
Scientific title
A placebo-controlled RCT of the use of probiotics to reduce depressive symptoms in adults with depression
Secondary ID [1] 287471 0
NIL
Universal Trial Number (UTN)
U1111-1174-3877
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Depression 296204 0
Condition category
Condition code
Mental Health 296482 296482 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The intervention in this trial will be a probiotic supplied by Winclove Probiotics. Participants will be asked to consume 2 x 2g of the probiotic daily over the course of 8 weeks by dissolving the freeze-dried powder in water and drinking it, and provide weekly measures of mood and depression during this period. Pre and post-measures of depressive symptoms will be taken prior to and after the conclusion of the 8 week probiotic period.
The probiotic powder contains the following ingredients: maize starch, maltodextrins, +/- probiotic bacteria (B. bifidum W23, B. lactis W52; L. acidophilus L37; L. brevis W63, L. casei W56; L. salivarius W24; Lc. lactis W19 and W58), minerals, vegetable protein. The number of Colony Forming Units (CFU) is 2.5 x 10^9 CFU/gram. Participant adherence to probiotic consumption will be monitored through asking them to record how many sachets they took each day, as well as returning of both empty and full probiotic sachets to the research team each week.
Intervention code [1] 292854 0
Treatment: Other
Comparator / control treatment
The control group will be a placebo control. Participants in this group will be given a freeze-dried powder containing the same ingredients minus the active probiotics as the intervention group, and the placebo and probiotic will be identical in terms of taste, appearance and smell. Participants will consume 2 x 2g of the placebo daily over an 8 week period. The control group will complete the same pre and post-measures of depressive symptoms, as well as weekly measures of mood and depression during the 8 week probiotic/placebo period.
Control group
Placebo

Outcomes
Primary outcome [1] 296109 0
Proportion of participants with subclinical or clinical diagnosis of Major Depressive Disorder (MDD), on the Mini International Neuropsychiatric Interview (M.I.N.I)
Timepoint [1] 296109 0
baseline, post-intervention (8 weeks)
Primary outcome [2] 296110 0
mean score on the Beck Depression Inventory – II
Timepoint [2] 296110 0
baseline, post-intervention (8 weeks)
Primary outcome [3] 296111 0
mean score on the Depression Anxiety Stress Scale-21
Timepoint [3] 296111 0
weekly, beginning at baseline through to the end of the intervention period (8 weeks)
Secondary outcome [1] 317532 0
mean score on Beck Anxiety Inventory
Timepoint [1] 317532 0
baseline, post-intervention (8 weeks)
Secondary outcome [2] 317533 0
mean score on Cognitive Reactivity Scale
Timepoint [2] 317533 0
baseline, post-intervention (8 weeks)

Eligibility
Key inclusion criteria
Participants must be aged 18 years or above, and at screening have a subclinical or clinical diagnosis of Major Depressive Disorder confirmed using the Mini International Neuropsychiatric Interview (M.I.N.I). Participants must be able to travel to UTS (Ultimo) to participate in the study, and must have access to and regularly check a valid email address. Participants must also be willing to complete questionnaires measuring mood, general wellbeing and health, as well as a measure of blood pressure and a stool sample
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Key exclusion criteria: Participants will be excluded from the trial if they meet any of the following restrictions: currently taking antibiotics or probiotic supplements, taken antibiotics within the 2 weeks prior to the start of the trial, diagnosed with HIV/AIDS, cancer, Crohn’s disease or ulcerative colitis, currently undergoing chemotherapy, lactose-intolerant, gluten-intolerant, high-risk alcohol consumption, experiencing severe depressive symptoms, actively suicidal or experiencing severe suicidal ideation, actively self-harming, pregnant or planning to be pregnant within the time-course of this study, diagnosed with Bipolar disorder, a Personality disorder, a psychotic disorder or otherwise experiencing psychosis, receiving any other treatment for mental health issues (including medications such as anti-depressants) or currently participating in another clinical trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be randomly allocated to the control or intervention groups, through use of a computerised randomiser. Probiotics/placebos will be allocated and labelled prior to the commencement of the trial, and research team members will not know participant allocation during the trial and data analysis period. After data has been analysed, and any direction of effect noted, treatment allocation will be unblinded.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The method of sequence generation will be through using a computerised randomiser.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
N/A
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Sample size was calculated by a review of the literature on studies for depression treatment, with a focus on the expected effect size. Klein, Jacobs and Reinecke (2007) indicate that an effect size of 0.53 (medium effect size) is the average for CBT trials on depression, which was reflected in the literature we reviewed. A power analysis via the program G*Power (computerised statistical program, Universitat Dusseldorf) indicated that 36 participants per group would be required to detect a medium effect size with 80% power. This is a total of 72 participants.
Further statistical analyses will involve an ANCOVA holding pre-existing baseline measures of depressive symptoms and anxiety as co-variates. Based on previous literature, a sample size of 36 participants per group is large enough to encompass a range of depression severities.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
22/03/2016
Actual
12/04/2016
Date of last participant enrolment
Anticipated
Actual
6/03/2017
Date of last data collection
Anticipated
Actual
23/05/2017
Sample size
Target
72
Accrual to date
Final
71
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 292049 0
University
Name [1] 292049 0
University of Technology Sydney
Country [1] 292049 0
Australia
Primary sponsor type
University
Name
University of Technology Sydney
Address
Graduate School of Health, Building 7, UTS, 15 Broadway, Ultimo, NSW, 2007
Country
Australia
Secondary sponsor category [1] 290717 0
None
Name [1] 290717 0
Address [1] 290717 0
Country [1] 290717 0
Other collaborator category [1] 278625 0
Individual
Name [1] 278625 0
Dr Saskia van Hemert
Address [1] 278625 0
Winclove Probiotics
Winclove B.V. Hulstweg 11 1032 LB Amsterdam The Netherlands
Country [1] 278625 0
Netherlands

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 293530 0
UTS Human Research Ethics Committee
Ethics committee address [1] 293530 0
Ethics committee country [1] 293530 0
Australia
Date submitted for ethics approval [1] 293530 0
04/09/2015
Approval date [1] 293530 0
15/12/2015
Ethics approval number [1] 293530 0
UTS HREC REF NO. 2015000438

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 60330 0
Dr Lynette Roberts
Address 60330 0
Level 4, GSH, Building 7 UTS, 15 Broadway, Ultimo, NSW, 2007
Country 60330 0
Australia
Phone 60330 0
+61 2 9514 7202
Fax 60330 0
Email 60330 0
robe0774@flinders.edu.au
Contact person for public queries
Name 60331 0
Lynette Roberts
Address 60331 0
Level 4, GSH, Building 7 UTS, 15 Broadway, Ultimo, NSW, 2007
Country 60331 0
Australia
Phone 60331 0
+61 2 9514 7202
Fax 60331 0
Email 60331 0
robe0774@flinders.edu.au
Contact person for scientific queries
Name 60332 0
Lynette Roberts
Address 60332 0
Level 4, GSH, Building 7 UTS, 15 Broadway, Ultimo, NSW, 2007
Country 60332 0
Australia
Phone 60332 0
+61 2 9514 7202
Fax 60332 0
Email 60332 0
robe0774@flinders.edu.au

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseGut feelings: A randomised, triple-blind, placebo-controlled trial of probiotics for depressive symptoms.2019https://dx.doi.org/10.1016/j.jad.2019.04.097
N.B. These documents automatically identified may not have been verified by the study sponsor.